Similar Articles |
|
The Motley Fool February 24, 2011 Brian Orelli |
Continuing to Play Me-Too Onglyza is never going to catch Januvia. |
The Motley Fool May 18, 2011 Brian Orelli |
If You Can't Beat 'Em, Use 'Em to Beat Your New Rival Merck is supposed to be a bitter rival to Roche in the hepatitis C space. Instead, it's extending the hand of friendship. |
The Motley Fool October 28, 2011 Brian Orelli |
Invest in Biotechs Going After Unmet Needs What a quarter it was for Vertex Pharmaceuticals: $420 million in net sales of its new hepatitis C drug. |
The Motley Fool July 29, 2011 Brian Orelli |
Vroom! There Goes Vertex Vertex Pharmaceuticals' Incivek launch is off to a good start. |
The Motley Fool September 9, 2008 Brian Orelli |
Drug Duo Combines Its Way Toward an Approval Bristol-Myers and AstraZeneca are trying to get their diabetes drug approved as a combination treatment. |
The Motley Fool April 28, 2011 Brian Orelli |
Victory for Victrelis Merck's hepatitis C drug moves one step closer to FDA approval. |
The Motley Fool April 3, 2007 Brian Lawler |
Merck Gets the Combo Merck gets marketing approval for a diabetes combination drug. Investors, take note. |
The Motley Fool September 30, 2011 Brian Orelli |
A Drug Market That's 366 Million Strong Diabetes drugs have potential. |
The Motley Fool May 17, 2011 Luke Timmerman |
Merck, Genentech Team Up on Hepatitis C Drug Merck pulling lots of strings to grab market share against Vertex. |
The Motley Fool October 22, 2008 Brian Orelli |
Merck's a Bloated Garbage Heap of Stale Drugs Now Merck is planning on cutting 12% of its workforce in the hopes of saving $4 billion through 2013. |
The Motley Fool September 28, 2009 Brian Orelli |
Here We Go Again With Possible Side Effects The FDA says it has received 88 reports of pancreatitis in patients taking Merck's Januvia and Janumet. |
The Motley Fool July 7, 2011 Brian Orelli |
J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo. |
The Motley Fool July 23, 2007 Brian Lawler |
Merck Not Hurt Merck repeats another nice quarter of bottom-line growth despite growing concerns about generic competition. |
The Motley Fool June 26, 2009 Brian Orelli |
Looking for a Sliver of the Me-Too Pie Another diabetes drug is close to hitting the market. |
The Motley Fool August 4, 2010 Brian Orelli |
No Nail Yet, but Vertex Creeps Up to Merck's Coffin Merck's hepatitis C data doesn't look as good as Vertex's. |
The Motley Fool October 23, 2006 Brian Lawler |
Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount. |
The Motley Fool October 31, 2011 Brian Orelli |
Gunning for the Leaders Hepatitis C drugs take center stage. |
The Motley Fool March 31, 2011 Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
The Motley Fool July 27, 2011 Brian Orelli |
Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication. |
The Motley Fool June 30, 2009 Brian Orelli |
A Cocktail for Drug Investors Drug cocktails aren't just for alchemists anymore. In many diseases they've become big business, and pharmaceutical investors would be smart to pay attention. |
The Motley Fool June 14, 2011 Brian Orelli |
Going for Seconds in the Hepatitis C Space Fresh from the Food and Drug Administration's approval of its hepatitis C drug, Incivek, Vertex has licensed a pair of hepatitis C compounds from privately held Alios BioPharma. |
The Motley Fool October 2, 2009 Brian Orelli |
Warning! Potential Blockbuster Ahead It's a little early to call it, but it looks like Bristol-Myers Squibb and AstraZeneca have a potential blockbuster on their hands with their new diabetes drug. |
The Motley Fool May 5, 2010 Brian Orelli |
Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is. |
The Motley Fool April 26, 2011 Brian Orelli |
There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost. |
The Motley Fool August 11, 2010 Brian Orelli |
Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients. |
The Motley Fool October 31, 2011 Brian Orelli |
5 One-Drug Wonders Going for No. 2 Here are five drugmakers hoping not to become one-hit wonders: Vertex... Onyx... Momenta... Elan... Dendreon... |
The Motley Fool May 18, 2009 Brian Orelli |
Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship. |
The Motley Fool September 8, 2010 Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
The Motley Fool September 7, 2007 Brian Orelli |
Fighting the Generics Next Door Pfizer tries to stop patients from switching from it's patented Lipitor to generic Zocor by doing an observational study of patients on both medications. |
The Motley Fool July 15, 2010 Brian Orelli |
The Blockbuster Drug Survives Another Body Blow Avandia is still standing. |
The Motley Fool December 5, 2007 Brian Orelli |
Merck Stays Conservative Merck sets the bar low with its 2008 guidance. Is the company being overly cautious? |
The Motley Fool November 24, 2010 Brian Orelli |
Profit From the United States of Diabetes Half the country could have an early form by 2020. |
The Motley Fool January 19, 2012 Brian Orelli |
New Hep C Data Impressive, but It's Not There Yet All-oral treatment still has a ways to go. |
The Motley Fool February 16, 2010 Brian Orelli |
Merck Gets a Pass, for Now Its first quarter looks promising, but not as good as could be hoped. |
The Motley Fool April 17, 2007 Brian Lawler |
Merck Raises the Earnings Roof Shares of Merck soar after it raises 2007 earnings guidance. |
The Motley Fool April 29, 2008 Brian Orelli |
Merck's Recovery Flushed Down Merck's best hope at recovery fails approval by the FDA. |
The Motley Fool July 27, 2011 Alexander Crawford |
Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve? |
The Motley Fool July 18, 2008 Brian Orelli |
Foolish Forecast: How Quickly Can Merck Turn It Around? Views you can use to get clues on the news. |
The Motley Fool January 28, 2010 Brian Orelli |
The Next Amgen? Not Yet. Amylin Pharmaceuticals is in much the same situation as Amgen is in: relatively flat sales, and the potential for a nice boost from a Food and Drug Administration approval shortly. But that's where the comparison ends. |
The Motley Fool November 25, 2011 Dan Caplinger |
Has Merck Become the Perfect Stock? Like most other pharma companies, Merck is dealing with the imminent loss of patent protection on one of its blockbuster drugs. |
The Motley Fool April 30, 2011 Brian Orelli |
No Long-Term Guidance? No Problem! Looking good, Merck. |
The Motley Fool April 25, 2011 Luke Timmerman |
Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it? |
The Motley Fool June 22, 2004 Charly Travers |
Merck Pays Up for a Cancer Drug As demonstrated this morning with the announcement of a major deal with Vertex Pharmaceuticals, Merck is now in the midst of a strategic push to build out its oncology pipeline. |
The Motley Fool April 24, 2009 Brian Orelli |
Great Drugs Not Living Up to Their Potential How well a drug works is not the most important thing to consider when investing. Drugs that work don't always become blockbusters. |
The Motley Fool August 23, 2004 Ben McClure |
Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest. |
The Motley Fool January 21, 2011 Brian Orelli |
Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir. |
The Motley Fool February 20, 2008 Brian Orelli |
Abbott's Copycat Combinations Abbott's latest FDA approval is for Simcor, a combination of Niaspan -- Abbott's slow-release niacin -- and the active component of Merck's Zocor, which isn't patent-protected anymore. Investors take note. |
The Motley Fool November 2, 2011 David Williamson |
After Hours: Dendreon's Shares Crushed Again Bad guidance in third quarter earnings punishes this stock. |
BusinessWeek July 26, 2004 Amy Barrett |
Hooked On The Cash From Cholesterol Cholesterol-lowering drugs are massive moneyspinners. But can big pharmaceutical companies sidestep expiring patents? |
The Motley Fool January 31, 2007 Brian Lawler |
Merck Plays the Waiting Game New acquisitions may help the drugmaker weather tough times. Investors, take note. |